Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants

(2015) Takeru Chigira et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The changing role of ER in endocrine resistance

(2015) Agostina Nardone et al.   BREAST

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

(2015) J. S. Frenel et al.   CLINICAL CANCER RESEARCH

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

(2015) D. Chu et al.   CLINICAL CANCER RESEARCH

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

(2015) P. Wang et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) D. S. Guttery et al.   CLINICAL CHEMISTRY

Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

(2015) David Sefrioui et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

(2015) Andiliy Lai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

(2015) Chris De Savi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

(2015) Gaia Schiavon et al.   Science Translational Medicine

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

(2014) Timothy R. Wilson et al.   BREAST CANCER RESEARCH AND TREATMENT

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2014) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

(2013) Paolo A. Ascierto et al.   JOURNAL OF CLINICAL ONCOLOGY

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

The search for ESR1 mutations in breast cancer

(2013) Steffi Oesterreich et al.   NATURE GENETICS

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

(2013) Leticia De Mattos-Arruda et al.   Nature Reviews Clinical Oncology

Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE